Editorial (Letter from the Editor-in-Chief of Current Radiopharmaceuticals)

Dear Colleague Since the conception of Current Radiopharmaceuticals in January 2008, we have been inundated with a variety of research articles ranging from topics discussing the use of radiopharmaceuticals in imaging, drug discovery to targeted alpha therapy. All these, articles have been peer reviewed by the journal's editorial board. Here, I would personally like to take this opportunity to thank everyone on the journals board that has volunteered unlimited time to review many articles that we have received and the editorial staff at Bentham Science. This new journal has captured the imagination of many scientists working in nuclear medicine. The journal owes its success to the number of authors who have submitted high quality manuscripts sharing in-depth knowledge in the area of radiopharmaceuticals. The second volume in 2009 in succession of the reputation of the first volume will also comprise of three issues. One focus of the journal is to give a clinical overview of some of the articles. This was first done by Mansi et al. in volume one issue three in which he summarizes the clinical aspects of ‘Targeted Alpha Particle Therapy’. In addition, we attempted to ‘group’ articles together to constitute a thematic issue, the first issue of volume one where the guest editors Kalevi Kairemo and Kim Bergstrom compiled an issue on the topic ‘The Role of Radiopharmaceuticals in Drug Discovery’; Ganesan Vaidyanathan and Roy Larsen on ‘Targeted Alpha Particle Therapy’ continued this thematic approach. The idea behind thematic issues is to generate maximum impact to the published subject matter in that particular area of radiopharmaceuticals to drive the journals' impact factor. Finally, we have some very interesting articles and reviews, which will be published in the forthcoming issues. The journal is growing fast and so is its reputation amongst researchers in pharmaceutical companies, institutions and universities; all of this will lead to the future success of Current Radiopharmaceuticals. Kind regards